Results 21 to 30 of about 5,721 (196)
Nebivolol in the treatment of chronic heart failure
Vascular Health and Risk Management, 2007 Angie Veverka, Jennifer L SalinasWingate University School of Pharmacy, Wingate, NC, USAAbstract: Nebivolol is a highly selective beta1-adrenergic blocker that also enhances nitric oxide bioavailability via the L-arginine-nitric oxide pathway, leading to
Angie Veverka, Jennifer L Salinas
doaj +1 more source
Beneficial Effects of Nebivolol in Comparison with Atenolol on Safety and Tolerability in Essential Hypertension [PDF]
Journal of Clinical and Diagnostic Research, 2014 Introduction: Hypertension, “The silent killer” is a multifactorial disorder which is asymptomatic and if left untreated leads to lethal complications.
Vivek V. Bhosale +5 more
doaj +1 more source
Nebivolol: impact on cardiac and endothelial function and clinical utility [PDF]
, 2012 Jorge Eduardo Toblli1, Federico DiGennaro1, Jorge Fernando Giani2, Fernando Pablo Dominici21Hospital Aleman, 2Instituto de Química y Fisicoquímica Biológicas (IQUIFIB), Facultad de Farmacia y Bioquímica ...
Dominici FP +3 more
core +2 more sources
The Beta-1-Receptor Blocker Nebivolol Elicits Dilation of Cerebral Arteries by Reducing Smooth Muscle [Ca2+]i. [PDF]
PLoS ONE, 2016 Nebivolol is known to have beta-1 blocker activity, but it was also suggested that it elicits relaxation of the peripheral arteries in part via release of nitric oxide (NO).
Peter Cseplo +5 more
doaj +1 more source
MODERN POTENTIAL IN THE TREATMENT OF METABOLIC SYNDROME PATIENTS - FOCUS ON ENDOTHELIUM
Российский кардиологический журнал, 2014 Numerous publications on the use of p-blockers in patients with arterial hypertension (AH) and metabolic syndrome (MS) have reported adverse effects of these medications on carbohydrate and lipid metabolism, as well as reduced cerebral perfusion.
V. B. Mychka +5 more
doaj +1 more source
Рациональная фармакотерапия в кардиологии, 2016 Aim. To evaluate influence of long-term monotherapy with nebivolol on blood pressure (BP) (office BP; self-monitoring BP, pre-trip BP monitoring, ambulatory BP monitoring (ABPM)) and metabolic blood profile in locomotive crew staff with newly diagnosed ...
I. V. Osipova +6 more
doaj +1 more source
American Journal Cardiovascular Drugs, 2009 Nebivolol is a beta-adrenergic receptor antagonist with a dual mechanism of action. It shows high selectivity for beta(1)-adrenergic receptors and appears to have nitric oxide-mediated vasodilatory activity. Once-daily nebivolol effectively lowered BP in patients with mild to moderate hypertension in four randomized, double-blind, placebo-controlled ...
Claudine M, Baldwin, Susan J, Keam
openaire +3 more sources
Frontiers in Medicine, 2022 BackgroundTenofovir disoproxil fumarate (TDF), a widely prescribed component in antiretroviral regimens, has been associated with nephrotoxicity. Nebivolol is a third generation selective β-1 adrenergic receptor blocker and may protect renal structure ...
Mariana Moura Nascimento +6 more
doaj +1 more source
Analytical approaches for the determination of Nebivolol [PDF]
Records of Pharmaceutical & Biomedical Sciences, 2022 A highly selective ẞ1-adrenergic receptor antagonist, nebivolol has a unique pharmacologic profile from other medications in its class. Nebivolol causes nitric oxide-mediated vasodilation in addition to cardioselectivity mediated by ẞ1 receptor blockage ...
Fathalla Belal +4 more
doaj +1 more source
Does the beta-blocker nebivolol increase coronary flow reserve? [PDF]
, 2007 INTRODUCTION: Nebivolol, a highly selective beta1-adrenergic receptor-blocker, increases basal and stimulated endothelial nitric oxide (NO)-release. It is unknown, whether coronary perfusion is improved by the increase in NO availability.
Hess, Otto M +8 more
core +1 more source